Skip to content

BioLife Solutions BLFS Accrued expenses and other liabilities

Accrued expenses and other liabilities at other companies

Revvity logo
RevvityRVTY
Labcorp Holdings logo
Labcorp HoldingsLH

Other financials

Income statement

See full
Revenue$27.5M+24.7%
Gross profit$17.5M+18.2%
Operating income$27.0K+105%
Net income$1.2M+365%
EPS (diluted)$0.02

Balance sheet

See full
Cash & equivalents$22.8M-65.9%
Total debt$17.4M-35.6%
Total equity$372.2M+5.6%
Total assets$400.9M+1.5%

Cash flow

See full
Operating cash flow-$491.0K-128%
CapEx$167.0K-4.6%
Free cash flow-$658.0K-142%

Valuation

See full
Market cap$1.34B+33.1%
Enterprise value$1.34B+38.1%
P/S13.5×+0.6×

Profitability

See full
Gross margin66.9%
Operating margin-16.7%
Net margin-68.7%
FCF margin-15.9%+18.7pp

Returns & leverage

See full
Return on equity-14.5%-4.7pp
Debt / equity0.0×
Current ratio7.3×+2.6×

Where this comes from

Reported directly by BioLife Solutions in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.

The official record: BioLife Solutions’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioLife Solutions's accrued expenses and other liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioLife Solutions's accrued expenses and other liabilities?
BioLife Solutions (BLFS) reported accrued expenses and other liabilities of -$4.4M in Q1 2026.
How has BioLife Solutions's accrued expenses and other liabilities changed year-over-year?
BioLife Solutions's accrued expenses and other liabilities decreased by 3.5% year-over-year, from -$4.25M to -$4.4M.